Arcus Biosciences' Losses Widen Amid Increased R&D Spend

Ticker: RCUS · Form: 10-Q · Filed: Oct 28, 2025 · CIK: 1724521

Sentiment: bearish

Topics: Biotechnology, Clinical Trials, Oncology, R&D Spending, Net Loss, Cash Burn, Gilead Collaboration

Related Tickers: RCUS, GILD

TL;DR

**RCUS is burning cash fast with widening losses, but their substantial R&D spend on a Phase 3 asset could be a game-changer if trials succeed; otherwise, expect more pain.**

AI Summary

Arcus Biosciences, Inc. (RCUS) reported a net loss of $135 million for the three months ended September 30, 2025, a significant increase from the $92 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss widened to $247 million, compared to $189 million in the prior year. Total revenues decreased to $26 million for the three months ended September 30, 2025, down from $48 million in 2024, and to $214 million for the nine months, down from $232 million. This decline was primarily driven by a reduction in license and development services revenue from a related party (Gilead Sciences, Inc.), which fell from $23 million to $20 million in the quarter and from $179 million to $192 million for the nine months. Research and development expenses increased to $141 million for the quarter, up from $123 million, and to $402 million for the nine months, up from $347 million, reflecting continued investment in their clinical-stage pipeline, including their anti-TIGIT antibody in Phase 3 studies. The company maintains $841 million in cash, cash equivalents, and marketable securities as of September 30, 2025, which they believe is sufficient to fund operations for at least 12 months.

Why It Matters

Arcus Biosciences' increasing net losses and declining revenue, despite a strong cash position, signal a critical period for investors. The company's heavy investment in R&D, particularly for its anti-TIGIT antibody in Phase 3 trials, is a high-stakes bet. Success in these trials could significantly boost investor confidence and market share in the competitive oncology space, potentially challenging established players. Conversely, trial failures or delays could lead to further stock depreciation and impact employee morale, while customers await potentially life-changing therapies. The ongoing collaboration with Gilead Sciences, Inc. remains a key factor, as its success or failure directly influences Arcus's financial trajectory and competitive standing.

Risk Assessment

Risk Level: high — Arcus Biosciences exhibits a high-risk profile due to a history of operating losses, with a net loss of $135 million for the three months ended September 30, 2025, and $247 million for the nine months. The company has never generated revenue from product sales and anticipates continued significant losses, as stated in the 'Risk Factor Summary'. Furthermore, the business heavily relies on the success of its investigational products in clinical trials and its collaboration with Gilead Sciences, Inc., both of which carry substantial inherent risks.

Analyst Insight

Investors should closely monitor the progress and results of Arcus's Phase 3 clinical trials, especially for the anti-TIGIT antibody, as these are critical catalysts. Given the high burn rate and reliance on collaboration revenue, consider this a speculative investment with potential for high reward if clinical milestones are met, but also significant downside risk if trials fail or are delayed.

Financial Highlights

debt To Equity
0.05
revenue
$26M
operating Margin
-546.15%
total Assets
$974M
total Debt
$98M
net Income
$-135M
eps
$-1.27
gross Margin
N/A
cash Position
$841M
revenue Growth
-45.83%

Revenue Breakdown

SegmentRevenueGrowth
License and development services revenue$20M-13.04%
Other collaboration revenue$6M-14.29%

Key Numbers

Key Players & Entities

FAQ

What were Arcus Biosciences' revenues for the third quarter of 2025?

Arcus Biosciences reported total revenues of $26 million for the three months ended September 30, 2025, which includes $20 million from license and development services revenue and $6 million from other collaboration revenue.

How much did Arcus Biosciences spend on research and development in Q3 2025?

Arcus Biosciences' research and development expenses for the three months ended September 30, 2025, totaled $141 million, an increase from $123 million in the same period of 2024.

What was Arcus Biosciences' net loss for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Arcus Biosciences reported a net loss of $247 million, compared to a net loss of $189 million for the same period in 2024.

What is the status of Arcus Biosciences' most advanced investigational product?

Arcus Biosciences' most advanced investigational product is an anti-TIGIT antibody, which is currently in multiple Phase 3 registrational studies targeting lung and gastrointestinal (GI) cancers.

What is Arcus Biosciences' liquidity position as of September 30, 2025?

As of September 30, 2025, Arcus Biosciences had cash, cash equivalents, and marketable securities totaling $841 million, which they believe will fund operations for at least twelve months.

What are the key risks for Arcus Biosciences investors?

Key risks for Arcus Biosciences investors include a history of operating losses, reliance on additional funding, the need to obtain regulatory approval for investigational products, and dependence on the collaboration with Gilead Sciences, Inc. for development and commercialization.

How has the collaboration with Gilead Sciences, Inc. impacted Arcus Biosciences' revenue?

Revenue from the related party, Gilead Sciences, Inc., for license and development services was $20 million in Q3 2025, down from $23 million in Q3 2024. For the nine months, it was $192 million, compared to $179 million in 2024.

Has Arcus Biosciences ever generated revenue from product sales?

No, Arcus Biosciences has a history of operating losses and has never generated any revenue from product sales, as stated in their risk factor summary.

What accounting standard updates will affect Arcus Biosciences in the future?

Arcus Biosciences plans to adopt ASU 2023-09 (Income Taxes) in early 2026, ASU 2024-03 (Income Statement Expenses) in early 2028, and is assessing ASU 2025-07 (Derivatives and Hedging) for potential impact, with an effective date of December 31, 2027.

What was the net loss per share for Arcus Biosciences in Q3 2025?

The basic and diluted net loss per share for Arcus Biosciences for the three months ended September 30, 2025, was $(1.27), compared to $(1.00) for the same period in 2024.

Risk Factors

Industry Context

The biotechnology industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Arcus Biosciences focus on developing novel therapies, often through collaborations, to share risk and leverage expertise. The competitive landscape is intense, with many companies vying for breakthroughs in areas like oncology.

Regulatory Implications

Arcus operates within a highly regulated pharmaceutical industry. Success is contingent on navigating complex FDA approval processes and adhering to stringent manufacturing and marketing standards. Any delays or failures in clinical trials or regulatory submissions can have severe financial and strategic consequences.

What Investors Should Do

  1. Monitor R&D spend and pipeline progress
  2. Analyze related party revenue trends
  3. Evaluate cash burn rate and runway
  4. Assess impact of share dilution

Key Dates

Glossary

License and development services revenue
Revenue generated from granting licenses for intellectual property and providing services related to the development of products. (A key revenue stream for Arcus, significantly impacted by related party transactions.)
Research and development (R&D) expenses
Costs incurred in the process of discovering, designing, and developing new products or improving existing ones. (Represents a major expenditure for Arcus, reflecting ongoing investment in its drug pipeline.)
Net loss per share
The portion of a company's profit or loss allocated to each outstanding share of common stock. (Indicates the profitability on a per-share basis, which has worsened for Arcus.)
Marketable securities
Investments that are readily convertible to cash, such as stocks and bonds. (A significant component of Arcus's liquid assets, contributing to its cash position.)
Deferred revenue
Revenue that has been received by the company but not yet earned, as the goods or services have not been provided. (Represents future revenue obligations, with a notable portion related to a related party.)
Dilution
A decrease in the earnings per share or ownership percentage of a company's stock that results from the issuance of new shares. (Occurs due to an increase in shares outstanding, impacting existing shareholders.)

Year-Over-Year Comparison

Compared to the prior year, Arcus Biosciences has experienced a significant increase in net losses, with Q3 2025 losses at $135 million versus $92 million in Q3 2024, and nine-month losses at $247 million versus $189 million. Total revenues have declined, with Q3 2025 revenues at $26 million compared to $48 million in Q3 2024. R&D expenses have notably increased, reflecting continued investment in the pipeline, which contributes to the widening deficit. The company also shows an increase in long-term debt and a rise in outstanding shares, indicating potential dilution.

Filing Stats: 4,712 words · 19 min read · ~16 pages · Grade level 15.1 · Accepted 2025-10-28 16:12:26

Key Financial Figures

Filing Documents

Financial Statements

Financial Statements 1 Condensed Consolidated Statements of Operations 1 Condensed Consolidated Statements of Comprehensive Loss 2 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4.

Controls and Procedures

Controls and Procedures 30 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 64 Item 3. Defaults Upon Senior Securities 64 Item 4. Mine Safety Disclosures 64 Item 5. Other Information 64 Item 6. Exhibits 65

SIGNATURES

SIGNATURES 66 Table of Contents RISK FACTOR SUMMARY The following is a summary of the key risks and uncertainties that make an investment in our securities speculative and risky. The below summary does not contain all of the information that may be important to you, and you should read this summary together with the more detailed description of the risks set forth under "Part II. Item 1A. Risk Factors" of the Quarterly Report. Risks Related to our Limited Operating History, Financial Position and Capital Requirements We have a history of operating losses, have never generated any revenue from product sales and anticipate that we will continue to incur significant losses for the foreseeable future. We may need to obtain additional funding. If we do not receive or are unable to raise additional capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs. Risks Related to the Discovery and Development of our Investigational Products If we are unable to obtain regulatory approval for our investigational products, or experience significant delays in doing so, our business will be materially harmed. Preliminary, topline and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available. Enrollment and retention of subjects in clinical trials is expensive and time consuming and can be made more difficult or rendered impossible by competing treatments, clinical trials of competing investigational products, geopolitical instability and public health epidemics, each of which could result in significant delays and additional costs in our product development activities, or in the failure of such activities. Serious adverse events, undesirable side effects or other unexpected properties of our investigational products ma

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ARCUS BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except per share amounts) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues: License and development services revenue (Includes $ 20 , $ 23 , $ 192 and $ 179 from a related party) $ 20 $ 41 $ 192 $ 204 Other collaboration revenue (Includes $ 6 , $ 7 , $ 22 and $ 28 from a related party) 6 7 22 28 Total revenues 26 48 214 232 Operating expenses: Research and development (Includes $ 13 , ($ 2 ), $ 19 and ($ 32 ) from a related party) 141 123 402 347 General and administrative (Includes $ 3 , $ — , $ 5 , and $ — from a related party) 27 30 84 92 Impairment of long-lived assets (see Note 12, Leases) — — — 20 Total operating expenses 168 153 486 459 Loss from operations ( 142 ) ( 105 ) ( 272 ) ( 227 ) Non-operating income (expense): Interest and other income, net 10 14 31 40 Interest expense ( 3 ) ( 1 ) ( 6 ) ( 2 ) Total non-operating income, net 7 13 25 38 Loss before income taxes ( 135 ) ( 92 ) ( 247 ) ( 189 ) Income tax expense — — — — Net loss $ ( 135 ) $ ( 92 ) $ ( 247 ) $ ( 189 ) Net loss per share: Basic and diluted $ ( 1.27 ) $ ( 1.00 ) $ ( 2.39 ) $ ( 2.11 ) Shares used to compute net loss per share: Basic and diluted 106.5 91.4 103.7 89.6 See accompanying notes. 1 Table of Contents ARCUS BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (In millions) (unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net loss $ ( 135 ) $ ( 92 ) $ ( 247 ) $ ( 189 ) Other comprehensive income — 2 — 1 Comprehensive loss $ ( 135 ) $ ( 90 ) $ ( 247 ) $ ( 188 ) See accompanying notes. 2 Table of Contents ARCUS BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except per share amounts) (unaudited) September 30, 2025 December 31, 2024 ASSETS Current asse

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing